Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Commentary|Videos|June 19, 2024
Cancer Hijacks Your Bone Marrow and Your Immune System: What Are You Going to Do About It?
Author(s)Thomas Marron, MD, PhD
Thomas Marron, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses the ways cancer attacks the bone marrow and immune system.
Advertisement
Advertisement
Related to this article
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Advertisement
Advertisement
Trending on OncLive
1
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
2
The OncFive: Top Oncology Articles for the Week of 10/11
3
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
4
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
5